Akero to expand ongoing Phase IIa trial of AKR-001 for NASH
Micrograph of non-alcoholic fatty liver disease (NAFLD). Credit: Nephron.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more